Skip to main content

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter ended April 30, 2022, on Thursday, July 21, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 908668. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46134, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/708456/Champions-Oncology-to-Announce-Fourth-Quarter-Financial-Results-on-Thursday-July-21-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.00
+3.73 (1.82%)
AAPL  271.79
+5.61 (2.11%)
AMD  213.66
+17.06 (8.68%)
BAC  50.41
-0.66 (-1.28%)
GOOG  311.10
-0.59 (-0.19%)
META  638.47
+1.22 (0.19%)
MSFT  388.02
+3.55 (0.92%)
NVDA  192.71
+1.16 (0.60%)
ORCL  145.53
+4.22 (2.98%)
TSLA  408.50
+8.67 (2.17%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.